Armata shareholders elect directors, approve advisory votes, ratify auditor at 2026 annual meeting

At the Meeting, our shareholders next approved, on a non-binding advisory basis, a one-year frequency for future advisory votes on the Company’s named executive officer compensation. The vote for such approval was 28,567,809 shares for one year, 2,400 shares for two years, 17,113 shares for three years, 4,914 shares abstaining, and 1,257,467 shares of broker non-votes.

At the Meeting, our shareholders next approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The vote for such approval was 28,547,283 shares for, 27,765 shares against, 17,188 shares abstaining, and 1,257,467 shares of broker non-votes.

At the Annual Meeting of Shareholders held on June 11, 2026 (the “Meeting”), the shareholders of Armata Pharmaceuticals, Inc. (the “Company”) elected seven members to our board of directors, each for a one-year term expiring at the annual meeting of shareholders in 2027, as follows: Members Number of Shares Voted For Number of Shares Withheld Broker Non- Votes Deborah L. Birx, M.D. 28,349,266 242,970 1,257,467 Daniel B. Gilmer, Ph.D. 28,543,542 48,694 1,257,467 Jules Haimovitz 28,350,690 241,546 1,257,467 Odysseas D. Kostas, M.D. 28,353,918 238,318 1,257,467 Robin C. Kramer 28,537,772 54,464 1,257,467 Joseph M. Patti, Ph.D. 28,544,094 48,142 1,257,467 Sarah Schlesinger, M.D. 28,354,046 238,190 1,257,467

Also at the Meeting, our shareholders ratified the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote for such ratification was 29,842,514 shares for, 6,631 shares against, 558 shares abstaining, and 0 shares of broker non-votes.